Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Liraglutide

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

Novo Nordisk · Phase 2 · Completed · Enrollment 706

NCT03856047

EudraCT 2018-001945-14

ArmNauseaVomitingDiarrheaDiscontinuationDeaths
NNC0174-0833, 4.5 mgn/rn/rn/rn/rn/r
NNC0174-0833, 2.4 mgn/rn/rn/rn/rn/r
NNC0174-0833, 1.2 mgn/rn/rn/rn/rn/r
NNC0174-0833, 0.6 mgn/rn/rn/rn/rn/r
NNC0174-0833 0.3 mgn/rn/rn/rn/rn/r
Placebo 2.4 mg (NNC0174-0833)32 participants9 participants18 participantsn/r0
Placebo 4.5 mg (NNC0174-0833)47 participants8 participants7 participantsn/r0
Placebo 1.2 mg (NNC0174-0833)37 participants5 participants8 participantsn/r0
Placebo 0.6 mg (NNC0174-0833)27 participants6 participants10 participantsn/r0
Placebo 0.3 mg (NNC0174-0833)20 participants6 participants15 participantsn/r0
Liraglutide 3.0 mgn/rn/rn/rn/rn/r
Placebo 3.0 mg (Liraglutide)39 participants20 participants18 participantsn/r0

A count stays a count. This page does not turn a count into a percent.